Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis

IF 12.8 1区医学 Q1 HEMATOLOGY

Leukemia Pub Date : 2025-03-20 DOI:10.1038/s41375-025-02552-3

Hira Mian, Thomas G. Martin, Gregory R. Pond, Sireesha Asoori, Rakesh Popat, Efstathios Kastritis, Joaquin Martinez-Lopez, Nadine Abdallah, Saurabh Chhabra, Ricardo Parrondo, Sikander Ailawadhi, Meletios A. Dimopoulos, Kwee Yong, Brian GM. Durie, Saad Z. Usmani, Yi Lin, Carlyn Rose Tan

{"title":"Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis","authors":"Hira Mian, Thomas G. Martin, Gregory R. Pond, Sireesha Asoori, Rakesh Popat, Efstathios Kastritis, Joaquin Martinez-Lopez, Nadine Abdallah, Saurabh Chhabra, Ricardo Parrondo, Sikander Ailawadhi, Meletios A. Dimopoulos, Kwee Yong, Brian GM. Durie, Saad Z. Usmani, Yi Lin, Carlyn Rose Tan","doi":"10.1038/s41375-025-02552-3","DOIUrl":null,"url":null,"abstract":"<p>Teclistamab, BCMA bispecific antibody (BsAb), was approved based upon the MajesTEC-1 study [1] with an overall response rate (ORR) of 63% and a median progression-free survival (PFS) of 11.3 months. In MajesTEC-1, the median age was 64 years, and patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥ 2 were excluded, suggesting that the vast majority of patients were fit. This has lead to a paucity of data both in clinical trials as well as in the real-world regarding the outcomes of older adults treated with BsAbs. We performed a retrospective analysis to understand the outcomes of older adults (age ≥ 70) including frail patients treated in the real-world with teclistamab.</p><p>This is was an multicenter retrospective study of patients with relapsed and/or refractory MM enrolled in the International Myeloma Foundation (IMF) immunotherapy database and treated with teclistamab at 7 academic centers across 5 countries between May 2022-Dec 2023. This study received approval from the Institutional Review Boards of the respective participating institutions and inidivdual patients were consented in accordance. Frailty categorization was done using the simplified frailty index and patients categorized as fit (score 0-1) or frail (≥ score 2) [2].</p>","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":"93 1","pages":""},"PeriodicalIF":12.8000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41375-025-02552-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Teclistamab, BCMA bispecific antibody (BsAb), was approved based upon the MajesTEC-1 study [1] with an overall response rate (ORR) of 63% and a median progression-free survival (PFS) of 11.3 months. In MajesTEC-1, the median age was 64 years, and patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥ 2 were excluded, suggesting that the vast majority of patients were fit. This has lead to a paucity of data both in clinical trials as well as in the real-world regarding the outcomes of older adults treated with BsAbs. We performed a retrospective analysis to understand the outcomes of older adults (age ≥ 70) including frail patients treated in the real-world with teclistamab.

This is was an multicenter retrospective study of patients with relapsed and/or refractory MM enrolled in the International Myeloma Foundation (IMF) immunotherapy database and treated with teclistamab at 7 academic centers across 5 countries between May 2022-Dec 2023. This study received approval from the Institutional Review Boards of the respective participating institutions and inidivdual patients were consented in accordance. Frailty categorization was done using the simplified frailty index and patients categorized as fit (score 0-1) or frail (≥ score 2) [2].

Abstract Image

查看原文本刊更多论文

特司他单抗治疗老年人（年龄≥70岁）虚弱亚组的结果：国际骨髓瘤基金会免疫治疗数据库真实世界分析

Teclistamab， BCMA双特异性抗体（BsAb），基于MajesTEC-1研究[1]获得批准，总缓解率（ORR）为63%，中位无进展生存期（PFS）为11.3个月。在MajesTEC-1中，中位年龄为64岁，排除了Eastern Cooperative Oncology Group (ECOG) performance status (PS)≥2的患者，提示绝大多数患者是适合的。这导致无论是在临床试验中还是在现实世界中，关于老年人接受bsab治疗的结果都缺乏数据。我们进行了一项回顾性分析，以了解老年人（年龄≥70岁）的结果，包括现实世界中使用teclistamab治疗的虚弱患者。这是一项多中心回顾性研究，纳入国际骨髓瘤基金会（IMF）免疫治疗数据库的复发和/或难治性MM患者，并于2022年5月至2023年12月在5个国家的7个学术中心接受teclistamab治疗。本研究得到了各参与机构的机构审查委员会的批准，患者个人也得到了同意。采用简化的衰弱指数进行衰弱分类，将患者分为健康（评分0-1）或虚弱（评分≥2）[2]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Leukemia 医学-血液学

CiteScore

18.10

自引率

3.50%

发文量

270

审稿时长

3-6 weeks

期刊介绍： Title: Leukemia Journal Overview: Publishes high-quality, peer-reviewed research Covers all aspects of research and treatment of leukemia and allied diseases Includes studies of normal hemopoiesis due to comparative relevance Topics of Interest: Oncogenes Growth factors Stem cells Leukemia genomics Cell cycle Signal transduction Molecular targets for therapy And more Content Types: Original research articles Reviews Letters Correspondence Comments elaborating on significant advances and covering topical issues